Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results [Yahoo! Finance]
Co-Diagnostics, Inc. (CODX)
US:NASDAQ Investor Relations:
ir.codiagnostics.com/investor-relations
Company Research
Source: Yahoo! Finance
for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024 Full Year 2024 Financial Results: Revenue of $3.9 million , which declined from $6.8 million during the prior year primarily due to higher Grant revenue in 2023. Grant revenue totaled $3.1 million while product revenue totaled $0.8 million Operating expenses of $43.0 million decreased by 5.2% from the prior year due to higher expenses in 2023 related to platform development and regulatory submission preparation Operating loss of $40.1 million compared to operating loss of $42.7 million in 2023 Net loss of $37.6 million , compared to net loss of $35.3 million in the prior year, representing a loss of per fully diluted share, compared to a loss of per fully diluted share in the prior year Adjusted EBITDA loss of $33.5 million Cash, cash equivalents, and marketable securities of $29.7 million as of December 31, 2024 Full Year 20
Show less
Read more
Impact Snapshot
Event Time:
CODX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CODX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CODX alerts
High impacting Co-Diagnostics, Inc. news events
Weekly update
A roundup of the hottest topics
CODX
News
- Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025PR Newswire
- Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, IndiaPR Newswire
- Co-Diagnostics (NASDAQ:CODX) was upgraded by analysts at Maxim Group to a "hold" rating.MarketBeat
- Co-Diagnostics (NASDAQ:CODX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $1.50 price target on the stock.MarketBeat
- Co-Diagnostics (NASDAQ:CODX) had its "neutral" rating reaffirmed by analysts at HC Wainwright.MarketBeat
CODX
Earnings
- 11/13/25 - Beat
CODX
Sec Filings
- 12/5/25 - Form 8-K
- 11/24/25 - Form 4
- 11/24/25 - Form 4
- CODX's page on the SEC website